The 17 references in paper N. Avxentyev A., M. Frolov Yu., Н. Авксентьев А., М. Фролов Ю. (2016) “Фармакоэкономическое исследование применения препарата Везомни (тамсулозин с контролируемым высвобождением + солифенацин) при нарушениях мочеиспускания, связанных с доброкачественной гиперплазией предстательной железы // PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA” / spz:neicon:pharmacoeconomics:y:2016:i:2:p:3-10

1
Data NES Center for Demographic Research (in Russian). URL: http://demogr.nes.ru/index.php/ru/demogr_indicat/data (accessed:
(check this in PDF content)
2
02.2016) 2. Incidence of the population of Russia in 2014: statistical data: in X hours [Zabolevaemost' naseleniya Rossii v 2014 godu: statisticheskie materialy: v X ch. (in Russian)] Moscow. 2015.
(check this in PDF content)
3
Sevryukov F. A. Complex medical-social and clinico-economic aspects of the prevention and treatment of benign prostatic hyperplasia. Dr. diss. [Kompleksnye mediko-sotsial'nye i kliniko-ekonomicheskie aspekty profilaktiki i lecheniya dobrokachestvennoi giperplazii predstatel'noi zhelezy (in Russian)]. Moscow. 2012; 309 s.
(check this in PDF content)
4
Bangalore S. et al. Fixed-dose combinations improve medication compliance: a meta-analysis. The American journal of medicine. 2007; 120 (8): 713-719.
(check this in PDF content)
5
Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? European urology. 1999; 36 (3): 7-13.
(check this in PDF content)
6
Chapple C. R. et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. European Urology Supplements. 2005; 4 (2): 33-44.
(check this in PDF content)
7
Drake M. J. et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. European urology. 2015; 67 (2): 262-270.
(check this in PDF content)
8
Hakimi Z. et al. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using The Health Improvement Network UK primary care data. Current medical research and opinion. 2015; 31 (1): 43-50.
(check this in PDF content)
9
Homma Y. et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. International journal of urology. 1997; 4 (1): 40-46.
(check this in PDF content)
10
LMMG New Medicine Recommendation. Vesomni for the treatment of Storage Symptoms associated with Benign Prostatic Hyperplasia. URL: http://www.lancsmmg.nhs.uk/wp-content/uploads/ sites/3/2014/05/MR140303-VESOMNI-CSU-New-Medicine-ReviewFinal-Recommendation-following-LMMG_WEBSITE.pdf (accessed: 23.02.2016).
(check this in PDF content)
11
Michel M. C. et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. European Urology Supplements. 2005; 4 (2): 53-60.
(check this in PDF content)
12
Mitropoulos D. et al. Symptomatic benign prostate hyperplasia: impact on partners’ quality of life. European urology. 2002; 41 (3): 240-245.
(check this in PDF content)
13
National Clinical Guideline Centre. The management of lower urinary tract symptoms in men. National Clinical Guideline Center, 2010. URL: http://www.nice.org.uk/usingguidance/commissioningguides/luts/ LUTS.jsp (accessed: 23.02.2016).
(check this in PDF content)
14
Nazir J. et al. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia . BMC urology. 2015; 15 (1): 1.
(check this in PDF content)
15
Oelke M. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European urology. 2013; 64 (1): 118-140.
(check this in PDF content)
16
Sexton C. C. et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU international. 2009; 103 (3): 12-23.
(check this in PDF content)
17
Toledo A. et al. Cost-Effectiveness Of A Fixed-Dose Combination Of Solifenacin Plus Tamsulosin Ocas For The Treatment Of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia In Spain. Value in Health. 2015; 18 (7): A510. Сведения об авторах:
(check this in PDF content)